3
|
Pelacho B, Lopez-Diaz De Cerio A, Inoges S, Perez-Astenaga I, Gavira JJ, Abizanda G, Andreu E, Crisostomo V, Bermejo J, Huss A, Gil AG, Koblizek T, Quintana LL, Fernandez-Aviles F, Prosper F. P5676Safety and immunomodulatory action of epicardial patches combined with allogeneic adipose-derived mesenchymal stem cells in a rodent and porcine model of myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- B Pelacho
- Center for Applied Medical Research, Stem Cell Area, Pamplona, Spain
| | | | - S Inoges
- Clinica Universidad de Navarra, Pamplona, Spain
| | - I Perez-Astenaga
- Center for Applied Medical Research, Stem Cell Area, Pamplona, Spain
| | - J J Gavira
- Clinica Universidad de Navarra, Pamplona, Spain
| | - G Abizanda
- Center for Applied Medical Research, Stem Cell Area, Pamplona, Spain
| | - E Andreu
- Clinica Universidad de Navarra, Pamplona, Spain
| | - V Crisostomo
- Jesus Uson Minimally Invasive Surgery Centre, Caceres, Spain
| | - J Bermejo
- University Hospital Gregorio Maranon, Madrid, Spain
| | - A Huss
- Viscofan BioEngineering, a business unit of Naturin Viscofan GmbH, Wenheim, Germany
| | - A G Gil
- University of Navarra, Pamplona, Spain
| | - T Koblizek
- Viscofan BioEngineering, a business unit of Naturin Viscofan GmbH, Wenheim, Germany
| | - L L Quintana
- Viscofan BioEngineering, a business unit of Naturin Viscofan GmbH, Wenheim, Germany
| | | | - F Prosper
- Clinica Universidad de Navarra, Pamplona, Spain
| |
Collapse
|
5
|
Baraibar I, Martin-Romano P, Mejías L, Perez Solans B, Ceniceros L, Legazpi J, Gardeazabal I, Inoges S, Lopez-diaz A, Idoate M, Cordoba A, Santisteban M. Abstract P2-04-01: Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Higher levels of TILs after neoadjuvant chemotherapy (NAC) in the residual tumor have been related to a better outcome in BC patients. According to International TILs working group (2014), we have quantified stromal TILs in a cohort of patients treated with NAC plus dendritic cell vaccines (cohort V) (NCT01431196 plus an expanded cohort) and in an historic cohort of patients treated with the same NAC without V (cohort C) in order to assess if the addition autologous dendritic cell vaccination pulsed with patient´s tumor lysates helps to increase TILs in the residual BC specimen. Our previous data with these cohorts of patients have shown an improved pCR and the stimulation of lymphocytes population in the peripheral blood from cohort V.
Methods: Classification of molecular subtypes was performed by IHC. We evaluated percentage of TILs by three different pathologists using stained HE core biopsy sections in paired samples taken at diagnosis (preNAC) and after surgery (postNAC) in a prospectively defined retrospective analysis.
Results: 79 patients were evaluated (cohort C 42; cohort V 37). Patients from V cohort were younger (p=0.01). Cohorts were well balanced for AJCC staging, molecular subtypes (cohort C: LA 26%, LB 45%, TN 29%; cohort V: LA 24%, LB 40%, TN 35%), stromal TILs preNAC [cohort C: median 9 (range, 1-24); cohort V: 6 (1-34); p=0.38] and stromal TILs postNAC [cohort C: 9 (2-52); cohort V 8 (4-50); p=0. 94]. Seventy-seven patients (97%) underwent surgery (cohort C 41; cohort V 36). Pathologic CR was higher in Cohort V (27% vs 7%; p=0.02). However a superior pCR rate was detected in TNBC subtype (cohort C 27%; cohort V 58%; p=0.15). Patients from Cohort V experienced an increment of stromal TILs after NAC plus autologous dendritic cell vaccination (preNAC: 6 (1-34); postNAC 8 (4-50); p=0.03), especially in TNBC [preNAC 14 (1-34); postNAC 30 (10-50); p=0.2]. A correlation analysis by Pearson´s R coefficient stated a strong association in V cohort between stromal TILs preNAC and postNAC (R=0.83) as well as a moderate correlation between stromal TILs postNAC and and molecular subtypes (R=0.6).
Table 1. Differences in Stromal TILs between studied cohorts PreNAC (median, range)PostNAC (median, range)P valueCohort C9 (1-66)9 (2-52)0.22Cohort V6 (1-34)8 (4-50)0.03*Cohort C LA LB TN5 (1-10) 9 (1-24) 12 (10-24)6 (3-12) 10 (2-40) 13 (5-52)0.69 0.17 1Cohort V LA LB TN5 (2-17) 6 (1-15) 14 (1-347 (4-12) 7 (4-27) 30 (10-50)0.18 0.08 0.2
Conclusion: Pathological complete responses were higher in BC patients treated with neoadjuvant chemotherapy plus active immunotherapy. The addition of autologous dendritic cell vaccines to NAC increases significantly stromal TILs in breast cancer patients.
Citation Format: Baraibar I, Martin-Romano P, Mejías L, Perez Solans B, Ceniceros L, Legazpi J, Gardeazabal I, Inoges S, Lopez-diaz A, Idoate M, Cordoba A, Santisteban M. Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-01.
Collapse
Affiliation(s)
- I Baraibar
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | | | - L Mejías
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - B Perez Solans
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - L Ceniceros
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - J Legazpi
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - I Gardeazabal
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - S Inoges
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - A Lopez-diaz
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - M Idoate
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - A Cordoba
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| | - M Santisteban
- Clinica Universidad de Navarra; Hospital Virgen del Camino
| |
Collapse
|
7
|
Pollack IF, Jakacki RI, Butterfield L, Okada H, Chiba Y, Hashimoto N, Kagawa N, Kinoshita M, Kijima N, Hirayama R, Oji Y, Tsuboi A, Oka Y, Sugiyama H, Yoshimine T, Valle RD, Tejada S, Inoges S, Idoate MA, de Cerio ALD, Espinos J, Aristu J, Gallego J, Calvo JP, Bendandi M, Zhu J, Chen C, Ravelo A, Yu E, Dhanda R, Schnadig ID, Zhang L, Fan H, Zhang I, Chen X, Wang H, Da Fonseca A, Badie B, Okada H, Butterfield LH, Hamilton RL, Mintz AH, Engh JA, Drappatz J, Lively MO, Chan MD, Salazar AM, Potter DM, Shaw EG, Lieberman FS, Wei J, Kong LY, Wang F, Xu S, Doucette TA, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB, Yang S, Archer GE, Miao H, Cui X, Xie W, Snyder D, Pretorian AJ, Dechkovskaia A, Reap E, Perez LAS, Norberg P, Schmittling R, Mitchell DA, Sampson JH, Wang F, Wei J, Gjyshi O, Kong LY, Xu S, Lang F, Calin G, Heimberger AB, Xu S, Wei J, Kong LY, Wang F, Calin G, Heimberger AB, Walker DG, Crough T, Beagley L, Smith C, Jones L, Khanna R, Hashimoto N, Tsuboi A, Chiba Y, Kijima N, Oka Y, Oji Y, Kinoshita M, Kagawa N, Yoshimine T, Sugiyama H, Kanemura Y, Sumida M, Yoshioka E, Yamamoto A, Kanematsu D, Matsumoto Y, Fukusumi H, Takada A, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Maekawa R, Shofuda T, Moriuchi S, Yamasaki M, Yeung JT, Hamilton R, Jakacki R, Okada H, Pollack I, Pellegatta S, Eoli M, Antozzi C, Frigerio S, Bruzzone MG, Cuppini L, Nava S, Anghileri E, Cantini G, Prodi E, Ciusani E, Ferroli P, Saini M, Broggi G, Mantegazza R, Parati EA, Finocchiaro G, Hegde M, Corder A, Chow KK, Mukherjee M, Brawley VS, Heslop HE, Gottschalk S, Yvon E, Ahmed N, Gibo DM, Debinski W, Bonomo J, Rossmeisl J, Robertson J, Dickinson P, Salacz ME, Camarata PJ, Ots M, McIntire J, Lovick D, Mitchell DA, Archer G, Bigner D, Friedman H, Lally-Goss D, Perry B, Herndon J, McGehee S, McLendon R, Coleman RE, Sampson J, Hegde M, Grada Z, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schonfeld K, Dotti G, Heslop H, Gottschalk S, Wels W, Baker ML, Ahmed N, Robbins JM, Dickinson PJ, York D, Sturges BK, Martin B, Higgins RJ, Bringas J, Bankiewicz K, Gruber HE, Jolly DJ, Narayana A, Mathew M, Kannan R, Madden K, Golfinos J, Parker E, Ott P, Pavlick A, Bota DA, Pretto C, Hantos P, Hofman FM, Chen TC, Carrillo JA, Schijns VE, Stathopoulos AA, Prins RM, Everson R, Soto H, Lisiero DN, Young E, Liau LM, Archer GE, Xie W, Norberg P, Dechkovskaia A, Friedman A, Bigner DD, Mitchell DA, Sampson JH, Boczkowski D, Mitchell DA, Gururangan SG, Grant G, Driscoll T, Archer G, King J, Boczkowski D, Xie W, Nair S, Perry B, Fuchs H, Kurtzberg J, Friedman H, Bigner D, Sampson J, Shevtsov MA, Pozdnyakov AV, Kim AV, Samochernych KA, Guzhova IV, Romanova IV, Margulis BA, Khachatryan WA. CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|